BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang XW, Li QH, Xu ZD, Dou JJ. STAT1-induced regulation of lncRNA ZFPM2-AS1 predicts poor prognosis and contributes to hepatocellular carcinoma progression via the miR-653/GOLM1 axis. Cell Death Dis 2021;12:31. [PMID: 33414427 DOI: 10.1038/s41419-020-03300-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Tang X, Miao Y, Wang J, Cai T, Yang L, Mi D. Identification of Mutator-Derived lncRNA Signatures of Genomic Instability for Promoting the Clinical Outcome in Hepatocellular Carcinoma. Comput Math Methods Med 2021;2021:1205029. [PMID: 34840594 DOI: 10.1155/2021/1205029] [Reference Citation Analysis]
2 Liu Y, Hu X, Liu S, Zhou S, Chen Z, Jin H. Golgi Phosphoprotein 73: The Driver of Epithelial-Mesenchymal Transition in Cancer. Front Oncol 2021;11:783860. [PMID: 34950590 DOI: 10.3389/fonc.2021.783860] [Reference Citation Analysis]
3 Yao Q, Zhang X, Chen D. Emerging Roles and Mechanisms of lncRNA FOXD3-AS1 in Human Diseases. Front Oncol 2022;12:848296. [DOI: 10.3389/fonc.2022.848296] [Reference Citation Analysis]
4 Xu B, Wei Y, Liu F, Li L, Zhou S, Peng Y, Li B. Long noncoding RNA CERS6-AS1 modulates glucose metabolism and tumor progression in hepatocellular carcinoma by promoting the MDM2/p53 signaling pathway. Cell Death Discov 2022;8:348. [PMID: 35927226 DOI: 10.1038/s41420-022-01150-x] [Reference Citation Analysis]
5 Xu W, Wu L, Lu H, Xiang X, Wang F, Li S. LncRNA PCGEM1 promotes colorectal cancer cell proliferation and migration in positive feedback loop through PCGEM1/miR-433-3p/CTCF axis. Pathol Res Pract 2022;237:154017. [PMID: 35872368 DOI: 10.1016/j.prp.2022.154017] [Reference Citation Analysis]
6 Zhang Y, Zhang Y, Wang S, Li Q, Cao B, Huang B, Wang T, Guo R, Liu N. SP1-induced lncRNA ZFPM2 antisense RNA 1 (ZFPM2-AS1) aggravates glioma progression via the miR-515-5p/Superoxide dismutase 2 (SOD2) axis. Bioengineered 2021;12:2299-310. [PMID: 34077295 DOI: 10.1080/21655979.2021.1934241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yan Y, Ren L, Liu Y, Liu L. Development and Validation of Genome Instability-Associated lncRNAs to Predict Prognosis and Immunotherapy of Patients With Hepatocellular Carcinoma. Front Genet 2022;12:763281. [DOI: 10.3389/fgene.2021.763281] [Reference Citation Analysis]
8 Wu J, Ren X, Wang N, Zhou R, Chen M, Cai Y, Lin S, Zhang H, Xie X, Dang C, Zhang S, Zhou Z. A Mutation-Related Long Noncoding RNA Signature of Genome Instability Predicts Immune Infiltration and Hepatocellular Carcinoma Prognosis. Front Genet 2021;12:779554. [PMID: 34880908 DOI: 10.3389/fgene.2021.779554] [Reference Citation Analysis]
9 Zhu Y, Shan D, Guo L, Chen S, Li X. Immune-Related lncRNA Pairs Clinical Prognosis Model Construction for Hepatocellular Carcinoma. IJGM 2022;Volume 15:1919-31. [DOI: 10.2147/ijgm.s343350] [Reference Citation Analysis]
10 Omorou M, Huang Y, Liu N, Bafei SEC, Gao M, Mu C, Zhang L, Hui X. The emerging role of miR-653 in human cancer. Cancer Epidemiol 2022;79:102208. [PMID: 35777307 DOI: 10.1016/j.canep.2022.102208] [Reference Citation Analysis]
11 Chen D, Wang M, Jiang X, Xiong Z. Comprehensive analysis of ZFPM2-AS1 prognostic value, immune microenvironment, drug sensitivity, and co-expression network: from gastric adenocarcinoma to pan-cancers. Discov Oncol 2022;13:24. [PMID: 35416526 DOI: 10.1007/s12672-022-00487-0] [Reference Citation Analysis]
12 Liu C, Gao J, Yang D, Yu Q, Zhang S. Title: Multi-Omics and Immune Landscape of Proliferative LncRNA Signatures: Implications for Risk Stratification and Immunotherapy in Hepatocellular Carcinoma. Front Pharmacol 2022;13:907433. [PMID: 35662721 DOI: 10.3389/fphar.2022.907433] [Reference Citation Analysis]
13 Sasa GBK, Xuan C, Lyu G, Ding X, Meiyu F. Long Non-coding RNA ZFPM2-AS1: A Novel Biomarker in the Pathogenesis of Human Cancers. Mol Biotechnol. [DOI: 10.1007/s12033-021-00443-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Mao Y, Ding Z, Jiang M, Yuan B, Zhang Y, Zhang X. Circ_0091579 exerts an oncogenic role in hepatocellular carcinoma via mediating miR-136-5p/TRIM27. Biomed J 2021:S2319-4170(21)00181-5. [PMID: 34974169 DOI: 10.1016/j.bj.2021.12.009] [Reference Citation Analysis]
15 Huang DP, Liao MM, Tong JJ, Yuan WQ, Peng DT, Lai JP, Zeng YH, Qiu YJ, Tong GD. Construction of a genome instability-derived lncRNA-based risk scoring system for the prognosis of hepatocellular carcinoma. Aging (Albany NY) 2021;13:24621-39. [PMID: 34799469 DOI: 10.18632/aging.203698] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ren H, Wei ZC, Sun YX, Qiu CY, Zhang WJ, Zhang W, Liu T, Che X. ATF2-Induced Overexpression of lncRNA LINC00882, as a Novel Therapeutic Target, Accelerates Hepatocellular Carcinoma Progression via Sponging miR-214-3p to Upregulate CENPM. Front Oncol 2021;11:714264. [PMID: 34513693 DOI: 10.3389/fonc.2021.714264] [Reference Citation Analysis]